N2OFF shares surge 10.23% intraday after rebranding to Nexentis and pivoting to AI-driven mitochondrial biotech targeting $120B markets.

N2OFF surged 10.23% intraday following its announcement of a corporate rebranding to Nexentis Technologies, reflecting a strategic pivot from cleantech to AI-driven computational biotech. The company emphasized integrating MitoCareX’s MITOLINE™ platform to target mitochondrial biology in oncology and inflammatory metabolic diseases, positioning itself in a $120 billion market by 2030. The rebranding, effective February 26, 2026, underscores a shift toward first-in-class drug discovery while retaining solar energy assets as non-core holdings. The move highlights confidence in leveraging computational biotech for pipeline development, aligning with investor enthusiasm for high-growth biotech opportunities.